ytb323
novartis
['ytb323', 'lymsm', 'car-t', 'lymphoma', 'dlbcl']
#eha2022 | , , presented a phase i study on ytb323, an autologous cd19-directed car-t cell, in r/r dlbcl. orr was 69% and responses appeared durable. a total of 10 (36%) pts experienced crs at dl2, 1 of which was grade 3/4 #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm